<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24946">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01754714</url>
  </required_header>
  <id_info>
    <org_study_id>M13-397</org_study_id>
    <secondary_id>2012-000975-18</secondary_id>
    <nct_id>NCT01754714</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group</brief_title>
  <acronym>EXPO</acronym>
  <official_title>Open-label, Randomized, Parallel-Group, Exploratory Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Non-treated Matched Healthy Volunteers as Control Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation the Effects of Different Doses of SAMe in Subjects with Nonalcoholic Fatty
      Liver Disease and non-treated matched healthy volunteers as control group
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Methionine elimination half-life measured in blood.</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting methionine concentration and AUC (area under curve) of average methionine concentration versus time curve, the metabolic clearance rate and volume of distribution measured in blood.</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>13C (natural, stable isotope of carbon) Methionine breath test</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>parameters cPDR30 , cPDR60, cPDR 90 (cumulative percentage dose of 13C recovered after 30, 60, 90 minutes), peak and time to peak will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Panel (liver laboratory parameters)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>STB (Serum Total Bilirubin), SCB (Serum Conjugated Bilirubin), liver-ALP (alkaline phosphatase), ALT (alanine aminotransferase), AST (aspartate aminotransferase), GGT (Gamma Glutamyl Transpeptidase), ALT/AST ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Panel (metabolic laboratory parameters)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fasting lipid profile (cholesterol, HDL (High Density Lipoprotein), LDL (Low Density Lipoprotein)), amino acid profile, homeostasis model assessment (HOMA-R) fasting plasma insulin, fasting glucose and glycosylated hemoglobin (HbA1c) as well as adiponectin</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunological/Anti-oxidant Panel (immunological and anti-oxidant laboratory parameters)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>CRP (C-reactive Protein), cytokine profile ( IL-6, IL-8, IL-10 (Interleukin),TNF-Î± (Tumor Necrosis Factor), MCP-1 (monocyte chemoattractant protein), and G-CSF (Granulocyte-colony stimulating factor )), glutathione in erythrocytes, oxidative stress marker (isoprostane level)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fibrosis and Apoptosis Markers (fibrosis and apoptosis laboratory markers)</measure>
    <time_frame>change from baseline at 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Caspase-cleaved CK 18 (cytokeratin) (M30) (monoclonal antibody 30), Hyaluronic acid, ActiTest/Fibrotest</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>1000 mg SAMe (S-adenosyl-L-methionine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1500 mg SAMe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2000 mg SAMe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAMe 1000 mg</intervention_name>
    <description>1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner</description>
    <arm_group_label>1000 mg SAMe (S-adenosyl-L-methionine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAMe 1500 mg</intervention_name>
    <description>1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner</description>
    <arm_group_label>1500 mg SAMe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAMe 2000 mg</intervention_name>
    <description>2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner</description>
    <arm_group_label>2000 mg SAMe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subjects with non-alcoholic steatohepatitis based on histology in medical history
             within the last 3 years

          -  Subjects in a stable metabolic condition since histology for NASH (Non-alcoholic
             Steatohepatitis)

        Exclusion Criteria

          -  Subjects with extrahepatic biliary obstruction

          -  Subjects with primary sclerosing  cholangitis (PSC)

          -  Subjects with primary biliary cirrhosis (PBC)

          -  Any form of malignancy within the past 5 years and/or basal cell carcinoma and
             squamous cell carcinoma of the skin within the past two years

          -  History of active substance abuse (oral, inhaled or injected) within one year prior
             to the study

          -  Subjects with renal impairment (creatinine level of &gt;2.0 mg/dL)

          -  Subjects with a known hypersensitivity to the active substance (ademetionine) or
             methionine or to any of the inactive ingredients

          -  Subjects with known genetic defects affecting the methionine cycle and/or causing
             homocystinuria and/or hyperhomocysteinemia (e.g., cystathionine beta-synthase
             deficiency, Vitamin B12 metabolism defect)

          -  Subjects on total parenteral nutrition in the year prior to screening

          -  Subjects after or planned for bariatric surgery (jejunoileal bypass or gastric weight
             loss surgery)

          -  Extrahepatic cholestasis (proven by ultrasound)

          -  Subjects with ALT (alanine aminotransferase) and/or AST (aspartate aminotransferase)
             &gt; 5 ULN (upper limit of normal)

          -  Subject with STB (serum total bilirubin) &gt; 5 ULN

          -  Subjects after liver transplantation and subjects on the waiting list for liver
             transplantation

          -  Subjects with any of the following disease in medical history:

          -  Viral hepatitis (serum positive HBcAb (hepatitis B core antibody) or HCV (Hepatitis C
             Virus) RNA (ribonucleic acid))

          -  Evidence of autoimmune liver disease

          -  Wilson's disease

          -  Hemochromatosis

          -  Alpha-1-antitrypsin deficiency

          -  Known positivity for antibody to human immunodeficiency virus (HIV)

          -  Known heart failure of New York heart Association class 3 or 4

          -  Current or history of significant alcohol consumption for a period of more than three
             consecutive months within five years prior to screening (significant alcohol
             consumption is defined as &gt; 3 U (unit)/day for men and &gt; 2 U/day for women, on
             average) or binge drinking or inability to reliably quantify alcohol consumption.

          -  Clinical or histological evidence of cirrhosis F4

          -  Subjects with history of biliary diversion

          -  Subjects with uncontrolled diabetes mellitus defined by  HbA1c (hemoglobin A1c) &gt; 8.0
             % at screening

          -  Concomitant medication of B12, folate, betaine or choline

          -  Concomitant treatment with glitazone within the past year prior to the study

          -  Subjects with known folate or B12 deficiency

          -  BMI (body mass index) &gt; 40 kg/m2

          -  History of major depression DSM-IV (diagnostic and statistical manual of mental
             disorders) or bipolar disease

          -  Women of childbearing potential: positive urine pregnancy test during screening or
             unwillingness to use an effective form of birth control during the study.

          -  Breastfeeding women

          -  Any condition that, in the opinion of the investigator, does not justify the
             patient's inclusion into the study

          -  Investigational drug intake within one month prior to the study

          -  Active, serious medical disease with likely life-expectancy less than five years

          -  Uncooperative attitude or reasonable likelihood for non-compliance with the protocol
             or any other reason that, in the investigator's opinion, prohibits the inclusion of
             the subject into the study

          -  Legal incapacity or limited legal capacity, or who are incarcerated.

          -  Inability to return for scheduled visits.

          -  Inability to understand and follow the requirements of the protocol in the local
             language
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suntje  Sander-Struckmeier, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gregor H. Eibes, PhD</last_name>
    <phone>+49 511 6750 2733</phone>
    <email>gregor.eibes@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suntje  Sander-Struckmeier, PhD</last_name>
    <phone>+49 511 6750 3254</phone>
    <email>suntje.sander@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID 93914</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93895</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93894</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93913</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93916</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93893</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93915</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93896</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93953</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93954</name>
      <address>
        <city>Frankfurt</city>
        <zip>60594</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93935</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93934</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93955</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93917</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93933</name>
      <address>
        <city>Homburg</city>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 94015</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93918</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 94014</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID/Investigator # 109455</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93958</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93973</name>
      <address>
        <city>Krakow</city>
        <zip>31-531</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93956</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93957</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93976</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93974</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID 93975</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000905</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000906</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000900</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000907</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000903</name>
      <address>
        <city>Omsk</city>
        <zip>644043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000920</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000904</name>
      <address>
        <city>Samara</city>
        <zip>443011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000901</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>December 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Steatohepatitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
